Pulmonary arterial hypertension (PAH) is a complex disease with a poor prognosis. In
recent years, great advances have occurred in our understanding of the pathophysiologic …

… R Badagliacca has received fees as speaker and scientific consultant for GSK, UT,
Dompè, Ferrer, Bayer, MSD, AOPOrphan Pharmaceuticals HiromiMatsubara: Advisory Board; …

… , although correlation coefficients were low (r=0.28, P=0.01 and r=0.26, P=0.02, respectively).
… Dr Poscia has received fees for serving as a speaker and consultant from Dompè and …

Background Pulmonary hypertension (PH) is a well-known independent prognostic factor in
chronic obstructive pulmonary disease (COPD) and a sufficient criterion for lung transplant …

Objective. Pulmonary arterial hypertension (PAH) is a complication of SSc due to increased
vascular resistance, and abnormal vascularity is a well-known feature of the disease as …

Heart failure (HF) represents a major health and economic issue, with increasing morbidity
and mortality in spite of novel therapeutic weapons. The disappointing results of HF …

Objectives : The aim of this study was to determine the prevalence of right intraventricular
dyssynchrony, its determinants and prognostic impact in idiopathic, heritable, and anorexigen-…

Background: Oral bosentan is an established treatment for pulmonary arterial hypertension (PAH).
Objective: To evaluate safety, tolerability, and clinical and haemodynamic effects of …

… A significant correlation was found between pulmonary vascular resistance and RV to
pulmonary arterial coupling (r = −0.55, r 2 = 0.31, p = 0.0001), with patients with RV mass/volume …

Background Right ventricular (RV) failure is a major determinant of symptoms and shortened
survival in pulmonary arterial hypertension (PAH). This study assessed the prognostic …